Pulse Biosciences is developing nsPFA technology for cardiac ablation to treat AFib and for ablating benign thyroid nodules.

Despite promising technology and FDA clearances, Pulse Biosciences lacks a revenue stream and remains in the testing phase ...

See how Pulse Biosciences, Inc.'s stock surged 100% despite no clear commercialization timeline, management turnover, and ...

The Company’s proprietary CellFX ® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is ...

--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today ...

Citi analyst Pat Cunningham adjusted the price target for Axalta Coating Systems (NYSE:AXTA), increasing it to $42.00, up from the previous $40.00, while keeping a Neutral rating on the stock.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present ...